N(4)-甲基-5-氮杂胞苷 | 27826-76-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: N(4)-甲基-5-氮杂胞苷
• 中文别名: 4-(甲基氨基)-1-(β-D-呋喃核糖基)-1,3,5-三嗪-2(1H)-酮
• 英文名称: 4-methylamino-1-β-D-ribofuranosyl-1H-[1,3,5]triazin-2-one
• 英文别名: N(4)-Methyl-5-azacytidine；1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(methylamino)-1,3,5-triazin-2-one
• CAS: 27826-76-2
• 化学式: C₉H₁₄N₄O₅
• 分子量: 258.234
• InChiKey: WVMPZTYBROSQRJ-DBRKOABJSA-N

物化性质

• 沸点：
  491.4±55.0 °C(Predicted)
• 密度：
  1.84±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  127
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 N(4)-甲基-5-氮杂胞苷
  参考文献：
  名称：

  Synthesis and Biological Activity of N4-Methyl-5-azacytidines

  摘要：

  通过对苯酰化的4-甲氧基-1-(β-D-核糖苷)-1,3,5-三嗪-2(1H)-酮5进行选择性氨解反应，制备了5-氮杂胞嘧啶的保护N4-甲基和N4,N4-二甲基衍生物3和4，通过对硅烷化的N4-甲基或N4,N4-二甲基-5-氮杂胞嘧啶7和8与2,3,5-三-O-苯酰-α,β-D-核糖苷氯化物(11)的糖基化反应，或通过异氰酸酯法的几种修饰方法制备。通过异氰酸酯法，还得到了保护的N4-甲基-5-氮杂胞嘧啶的α-D异构体17作为副产物。保护的二甲基衍生物4也可通过异丁脲22与二甲基甲酰胺二甲基缩醛反应得到。游离核苷1和2可通过游离的甲氧基核苷23分别与甲胺或二甲胺氨解，或通过相应的苯酰衍生物3和4的甲醇解或氨解得到。游离的α-D异构体24可通过其三苯甲酸酯17的甲醇解得到。核苷1和2的抗菌、抗肿瘤和抗病毒活性均低于未取代的5-氮杂胞嘧啶。

  DOI：

  10.1135/cccc19980713

文献信息

• [EN] CATIONIC LIPIDS AND USES THEREOF<br/>[FR] LIPIDES CATIONIQUES ET LEURS UTILISATIONS
  申请人：FACTOR BIOSCIENCE INC

  公开号：WO2021003462A1

  公开（公告）日：2021-01-07

  The present invention relates to novel cationic lipids of formula I, and more specifically formula IV. These are used, for example, in liposomes for the delivery of nucleic acids to cells.

  本发明涉及新型公式I的阳离子脂质，更具体地是公式IV。例如，这些脂质可用于脂质体中将核酸传递给细胞。
• METHODS AND PRODUCTS FOR TRANSFECTING CELLS
  申请人：FACTOR BIOSCIENCE INC.

  公开号：US20140356906A1

  公开（公告）日：2014-12-04

  The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

  本发明部分涉及编码蛋白质的核酸、含非规范核苷酸的核酸、包含核酸的治疗剂、诱导细胞表达蛋白质的方法、试剂盒和装置、转染、基因编辑和重编程细胞的方法、试剂盒和装置，以及使用这些方法、试剂盒和装置生产的细胞、生物体和治疗剂。公开了使用RNA诱导细胞表达蛋白质、重编程和基因编辑细胞的方法。还公开了从患者样本中制备细胞的方法、使用这些方法制备的细胞以及包含使用这些方法制备的细胞的治疗剂。
• METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY
  申请人：Factor Bioscience Inc.

  公开号：EP3690056A1

  公开（公告）日：2020-08-05

  The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules, including cells present in vivo. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.

  本发明部分涉及核酸，包括编码蛋白质的核酸，包含核酸的治疗剂和化妆品，向细胞、组织、器官和患者提供核酸的方法，使用核酸诱导细胞表达蛋白质的方法，用于转染、基因编辑和重编程细胞的方法、试剂盒和装置，以及使用这些方法、试剂盒和装置生产的细胞、生物体、治疗剂和化妆品。本文描述了改变细胞 DNA 序列的方法和产品，以及使用合成 RNA 分子诱导细胞（包括体内细胞）表达蛋白质的方法和产品。此外，还介绍了包含编码基因编辑蛋白的核酸的治疗方法。
• COMPOSITIONS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKIN
  申请人：KRYSTAL BIOTECH, INC.

  公开号：EP3712273A1

  公开（公告）日：2020-09-23

  The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.

  本公开部分涉及药物组合物，其包含一种或多种多核苷酸，适用于提高、增加、增强和/或补充受试者体内胶原蛋白α-1(VII)链多肽和/或赖氨酰羟化酶3多肽和/或角蛋白I型细胞骨架17多肽的水平。本公开还部分涉及药物组合物和使用方法，用于预防、缓解或治疗受试者（包括具有或有可能出现一种或多种表皮松解症症状的受试者）的皮肤伤口、紊乱或疾病。
• Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
  申请人：Krystal Biotech, Inc.

  公开号：US10155016B2

  公开（公告）日：2018-12-18

  The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.

  本公开部分涉及药物组合物，其包含一种或多种多核苷酸，适用于提高、增加、增强和/或补充受试者体内胶原蛋白α-1(VII)链多肽和/或赖氨酰羟化酶3多肽和/或角蛋白I型细胞骨架17多肽的水平。本公开还部分涉及药物组合物和使用方法，用于预防、缓解或治疗受试者（包括具有或有可能出现一种或多种表皮松解症症状的受试者）的皮肤伤口、紊乱或疾病。